OneMedNet Corp
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
ONMD$5.82-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(2,801) | $(10,129) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | 65 | 57 | ||
| Stock-based compensation expense | 2,032 | 628 | ||
| Stock warrant expense | - | 35 | ||
| Change in fair value of warrant liabilities | 56 | (9) | ||
| Change in fair value of convertible notes | (1,285) | 808 | ||
| Change in fair value of crypto assets – Bitcoin | 945 | (798) | ||
| Change in fair value of SEPA derivative liabilities | (216) | 434 | ||
| Realized gain on sale of crypto assets – Bitcoin | (922) | (120) | ||
| Gain on troubled debt restructurings | (5,569) | - | ||
| Loss on debt extinguishment | 41 | - | ||
| Non-cash SEPA commitment fee | - | 500 | ||
| Gain on forgiveness of CEBA loan | - | (15) | ||
| Non-cash interest | 45 | 121 | ||
| Change in operating assets and liabilities: | ||||
| Accounts receivable | (282) | (61) | ||
| Prepaid expenses and other current assets | 194 | 84 | ||
| Accounts payable and accrued expenses | 366 | 1,206 | ||
| Deferred revenues | (172) | 307 | ||
| Net cash used in operating activities | (7,503) | (6,952) | ||
| Cash flows from investing activities: | ||||
| Purchases of property and equipment | (13) | (51) | ||
| Purchases of crypto assets – Bitcoin | (2,750) | (2,900) | ||
| Proceeds from sales of crypto assets – Bitcoin | 5,070 | 969 | ||
| Net cash provided by (used in) investing activities | 2,307 | (1,982) | ||
| Cash flows from financing activities: | ||||
| Proceeds from private placements, net of issuance costs | 2,497 | 6,270 | ||
| Proceeds from related party subscription agreements, net of issuance costs | 1,697 | - | ||
| Proceeds from Yorkville SEPA | 2,537 | - | ||
| Proceeds from exercises of Helena Termination Warrants | 60 | - | ||
| Repayment of deferred underwriter fees | (500) | (100) | ||
| Repayment of Yorkville Note | (262) | - | ||
| Repayment of loans payable | (401) | (231) | ||
| Payment of issuance costs in connection with non-cash conversions of liabilities | (19) | - | ||
| Proceeds from issuance of shareholder loans | - | 2,000 | ||
| Proceeds from issuance of Yorkville Note, net of issuance costs | - | 1,350 | ||
| Proceeds from line of credit borrowings | - | 500 | ||
| Repayment of CEBA loan | - | (30) | ||
| Repayment of shareholder loan | - | (200) | ||
| Repayment of line of credit borrowings | - | (500) | ||
| Net cash provided by financing activities | 5,609 | 9,059 | ||
| Net increase in cash and cash equivalents | 413 | 125 | ||
| Cash and cash equivalents at beginning year | 172 | 47 | ||
| Cash and cash equivalents at end of year | $585 | $172 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for interest | $23 | $26 | ||
| Cash paid for taxes | $1 | $18 | ||
| Supplemental disclosures of non-cash investing and financing activities: | ||||
| Issuance of common stock in connection with settlement of vendor payable | $111 | $242 | ||
| Issuance of common stock upon partial conversions of Yorkville Note | $1,392 | $ | - | |
| Issuance of common stock upon conversions of loans with related parties | $2,334 | $ | - | |
| Issuance of common stock upon conversion of PIPE Notes | $510 | $ | - | |
| Issuance of common stock upon conversion of loan extensions with related parties | $2,584 | $ | - | |
| Insurance premium settled by issuance of note payable | $317 | $318 | ||
| Common stock repurchase consideration in loans payable | $312 | $329 | ||
| Common shares issued to partially settle deferred underwriter fees | $ | - | $242 | |
| Recognition of prepaid forward contract in exchange for partial conversion of Yorkville Note | $ | - | $343 | |
| Extinguishment of officer accrued salaries reclassified to additional paid-in capital | $ | - | $132 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.